Investigative Summary: Findings of Misconduct by a then Senior Official with the Drug Enforcement Administration for Misuse of Official Position Related to Giving Preferential Treatment to a Pharmaceutical Company, and Related Misconduct
- NARA ID
- investigative-summary-findings-misconduct-then-senior-official-drug-enforcement
- Source
- oig-doj
- Collection
- DOJ OIG — Drug Enforcement Administration
- Agency
- U.S. DOJ Office of the Inspector General
- Classification
- Investigation
- Released
- 2021-12-02
- Slug
- doj-oig-investigative-summary-findings-misconduct-then-senior-official-drug-enforcement
- Indexed
- 2026-04-27 05:02:45
More from DOJ OIG — Drug Enforcement Administration
- Review of the Drug Enforcement Administration's El Paso Intelligence Center
- Public Summary of the Addendum to the Audit of the Drug Enforcement Administration's Management and Oversight of its Confidential Source Program
- Management Advisory Memorandum – Notification of Concerns Relating to the DEA’s Untimely Reporting of Potential Human Rights Violations by Foreign Law Enforcement
- Audit of the Drug Enforcement Administration’s Use of Polygraphs in the Pre-employment and Foreign Vetting Processes
- Review of the Drug Enforcement Administration's Regulatory and Enforcement Efforts to Control the Diversion of Opioids
- Audit of the Drug Enforcement Administration's Personnel Resource Management and Casework
Browse all 59 documents in DOJ OIG — Drug Enforcement Administration →
About the DOJ OIG — Drug Enforcement Administration collection
U.S. DOJ Office of the Inspector General reports (audits, investigations, evaluations, and reviews) concerning Drug Enforcement Administration.